West Pharmaceutical Servs Earnings & Forecasts

West Pharmaceutical Servs (WST) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 23, 2026	$2.37	$2.08	13.9 %
Q1	Apr 23, 2026	$2.13	$1.68	26.8 %
Q4	Feb 12, 2026	$2.04	$1.83	11.5 %
Q3	Oct 23, 2025	$1.96	$1.68	16.7 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 23, 2026	$872.30M	$838.00M	4.09 %
Q1	Apr 23, 2026	$844.90M	$779.18M	8.44 %
Q4	Feb 12, 2026	$805.00M	$794.58M	1.31 %
Q3	Oct 23, 2025	$804.60M	$786.83M	2.26 %

West Pharmaceutical Servs Guidance

West Pharmaceutical Servs (WST)은 지난 7월 23, 2026에 fiscal year 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $8.85 - $9.05 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $8.61보다 높은 수치입니다. West Pharmaceutical Servs는 또한 해당 기간의 매출을 $3.35B - $3.38B 범위로 전망했습니다.

이전 가이던스와 비교하여 West Pharmaceutical Servs는 주당순이익(EPS) 전망치를 이전 범위인 상향 조정됨에서 $8.4 - $8.75로 상향 조정했습니다. 매출 측면에서는 회사가 매출 전망치를 이전 범위인 상향 조정됨에서 $3.29B - $3.35B로 상향 조정했습니다.

West Pharmaceutical Servs은 18과 10월 27, 2022 사이에 7월 23, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 13 times and lowered it 3 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$2.08	$1.68	$1.83	$1.68
Actual	$2.37	$2.13	$2.04	$1.96
Surprise	+13.9%	+26.8%	+11.5%	+16.7%
Revenue
Estimate	$838.0M	$779.2M	$794.6M	$786.8M
Actual	$872.3M	$844.9M	$805.0M	$804.6M
Surprise	+4.09%	+8.44%	+1.31%	+2.26%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$2.19	$2.27	$2.27	$2.53
Revenue
Consensus	$826.0M	$827.8M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.

Vandana Singh

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report

Benzinga Insights

PRO
West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est

West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380

Benzinga Newsdesk

West Pharmaceutical Services Inc